Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has granted a new US patent 7,935,528 to MultiCell Technologies for the isolation and use of human liver stem cells for the treatment of liver disease.
Subscribe to our email newsletter
As per the terms of its license agreement with Rhode Island Hospital, MultiCell Technologies is the worldwide exclusive licensee of US patent 7,935,528.
The patent covers the methods to isolate and use human liver stem cells to treat degenerative liver diseases, or inherited deficiencies of liver function.
MultiCell chairman and CEO Gerald Newmin said they are pleased the USPTO has agreed that their liver stem cells are indeed novel and may lead to important therapeutic applications.
"Our efforts to better understand liver stem cell biology, and the role these cells play in chronic liver disease and primary hepatocellular carcinoma, is a major focus of the Company," Newmin said.